



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/644,775
				Filing Date	08/21/2003
				First Named Inventor	Tennenbaum
				Art Unit	1647
				Examiner Name	Marianne P. Allen
Sheet	1	of	2	Attorney Docket Number	HEALOR-202

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	50	5,942,487	08-24-1999	Ogawa et al.	
	51	2005/054608	03-10-2005	Linge et al.	Corr. to US20080182780; GB2369572; WO0243751
	52	6,489,306	12-03-2002	Mohapatra et al.	
	53	6,841,472	01-11-2005	Mayuzumi	
	54	2004/0175384	09-09-2004	Mohapatra et al.	
	55	2008/0182780 A1	07-31-2008	Linge et al.	Corr. to GB2369572; WO0243751; US2005054608

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	56	GB 2 369 572	06-05-2002	RAFT Trustees Limited	Corr. to US 2008182780; WO0243751; US2005054608	
	57	EP 0 280 460	08-31-1988	Eli Lilly and Con.		
	58	WO 93/04691 A	03-18-1993	Life Medical Sciences, Inc.		
	59	WO 02/43751	06-06-2002	RAFT Trustees Ltd.	Corr. to GB2369572; US2005054608; US2008182780	
	60	WO 02/087576 A1	11-07-2002	Arach-Nova Therapeutics Ltd.		
	61	WO 2007/075911 A2	07-05-2007	Yale University		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	62	BELFIELD, et al.: "The use of INSULIN in open-wound healing", from a paper presented at 81 <sup>st</sup> Annual Convention of the California Veterinary Medical Association, October 3, 1969.	
	63	BRAIMAN-WIKSMAN, et al. "Novel Insights into Wound Healing Sequence of Events", <i>Toxicologic Pathology</i> , GB, Vol. 35, No. 6, (2007), pp. 767-779.	
	64	CATAISSON, et al. "Activation of Cutaneous Protein Kinase C $\alpha$ Induces Keratinocyte	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/644,775
				Filing Date	08/21/2003
				First Named Inventor	Tennenbaum
				Art Unit	1647
				Examiner Name	Marianne P. Allen
Sheet	2	of	2	Attorney Docket Number	HEALOR-202

		Apoptosis and Intraepidermal Inflammation by Independent Signaling Pathways", <i>J. of Immunol.</i> , US, Vol. 171, No. 5, (2003), pp. 2703-2713.	
	65	GREENWAY, et al.: "Topical insulin in wound healing: a randomised, double-blind, placebo-controlled trial", <i>J. Wound Care</i> , Vol. 8, No. 10 (1999) pp. 526-528	
	66	<a href="http://www.drugs.com/pdr/lletin_11.html">http://www.drugs.com/pdr/lletin_11.html</a> Information for patient	
	67	JONES, et al. "Staurosporine, a non-specific PKC inhibitor, induces keratinocyte differentiation and raises intracellular calcium, but Ro31-8220, a specific inhibitor does not", <i>J. of Cell. Physiol.</i> , Vol. 159, No.2, (1994), pp. 324-330; ABSTRACT XP-002520100, Database EMBASE [Online], Elsevier Science Publishers, Amsterdam, NL (1994).	
	68	KIRTON: Presentation at Symposium Keloids and Hypertrophic Scars, Grand Rounds, October 1999; <a href="http://www.uic.edu/depts/doms/rounds/rounds-35.html">http://www.uic.edu/depts/doms/rounds/rounds-35.html</a>	
	69	Lesion definition: <a href="http://216.251.232.159/semweb/internetsomd/ASP/1533197.asp">http://216.251.232.159/semweb/internetsomd/ASP/1533197.asp</a>	
	70	LIAO, et al. "Effect of $\alpha$ -Protein Kinase C Neutralizing Antibodies and the Pseudosubstrate Peptide on Phosphorylation, Migration, and Growth of REF52 Cells", <i>Cell Growth and Differentiation</i> , Vol. 4, No. 4, (1993), pp. 309-316	
	71	PAPP, et al. "Protein kinase C isozymes regulate proliferation and high cell density-mediated differentiation in HaCaT keratinocytes", <i>Experim. Dermatol.</i> , GB, Vol. 12, No. 6, (2003) pp. 811-824.	
	72	PIERRE, et al. "Effects of Insulin on Wound Healing", <i>J. of Trauma</i> , US, vol. 44, No. 2 (1998), pp. 342-345.	
	73	SHEN, et al. "A Divergence Point in the Signaling of Insulin and IGF-1-Induced Proliferation of Skin Keratinocytes", <i>Diabetes</i> , US, Vol. 50, No. 2 (2001), pp. 255-264.	
	74	STANWELL, et al. "Staurosporine induces a complete program of terminal differentiation in neoplastic mouse keratinocytes via activation of protein kinase C", <i>Carcinogenesis</i> , GB, (1996), Vol. 17, No. 6, pp. 1259-1265.	
	75	VARKEER, et al. "Involvement of the muscarinic acetylcholine receptor in inhibition of cell migration", <i>Biochem. Pharmacol.</i> , US, Vol. 63, No. 4, (2002), pp. 597-605.	
	76	WALLIS, et al. "The $\alpha$ Isoform of Protein Kinase C Is Involved in Signaling the Response of Desmosomes to Wounding in Cultured Epithelial Cells", <i>Molecular Biol. Of the Cell</i> , US, Vol. 11, No. 3, (2000), pp. 1077-1092.	
	77	YUSPA, et al. "Expression of Murine Epidermal Differentiation Markers Is Tightly Regulated by Restricted Extracellular Calcium Concentrations In Vitro", <i>J. of Cell Biol.</i> , US, Vol. 109, No. 3, (1989), pp. 1207-1217.	
	78	ANONYMOUS "Dulbecco's Phosphate Buffered Saline (D-PBS)", Internet Article ABSTACT from URL: <a href="http://www.hyclone.com/media/dulbeccos_phosphate.htm">http://www.hyclone.com/media/dulbeccos_phosphate.htm</a> >	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--